[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.98.119. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
April 1999

Efficacy of Erbium:YAG Laser Ablation in Darier Disease and Hailey-Hailey Disease

Author Affiliations

From the Department of Dermatology, J. W. Goethe University, Frankfurt, Germany.

Arch Dermatol. 1999;135(4):423-427. doi:10.1001/archderm.135.4.423
Abstract

Background  Among different surgical approaches, dermabrasion and carbon dioxide laser vaporization have been used to treat Hailey-Hailey disease (HHD) (familial benign chronic pemphigus) and Darier disease (DD) (keratosis follicularis), with various results. Because of the erbium:YAG laser's unique absorption characteristics in tissue water, erbium:YAG laser ablation combines the advantages of both techniques, avoiding thermal injury of vaporization and also allowing selectively deeper tissue removal in the follicular lesions of DD. Therefore, good results should be expected in both types of acantholytic disorders.

Observations  Four patients (2 with HHD and 2 with DD) with different affected areas were treated with laser ablation. During a follow-up period ranging from 8 to 20 months, complete remission was achieved in 3 patients—2 with DD and 1 with HHD—and significant improvement was achieved in 1 patient with HHD. Histological examination of control biopsy specimens after ablation in 1 patient with DD revealed no signs of the disease and only a slight fibrosis in the papillary dermis.

Conclusions  Erbium:YAG laser ablation effectively removes lesions of both HHD and DD and can also yield excellent long-term results in chronic, recalcitrant cases.

DARIER DISEASE (DD) (keratosis follicularis) and Hailey-Hailey disease (HHD) (familial benign chronic pemphigus) are autosomal dominant disorders characterized by specific alterations corresponding to seborrheic areas of the body and intertriginous areas.13 The histological features consist of dyskeratosis, suprabasal acantholysis, papillomatosis, and suprabasal separation with extensive loss of intercellular bridges.4 Despite the clinical and histological overlap of the 2 diseases, the underlying mutations of both affect different genes.5

Conventional therapeutic approaches consist of topical and systemic steroids, antibiotic agents, vitamin A acid cream, and oral retinoids. Nevertheless, prolonged remission is difficult to achieve.13

Good results for both diseases were obtained from such surgical interventions as excision6,7 or excision with subsequent split-thickness skin grafting,8 electrodesiccation,9 and dermabrasion.1014 According to the observations of other authors, our own experiences have confirmed the value of dermabrasion, particulary in the treatment of HHD. However, DD frequently requires selective removal of keratotic papules and circumscribed deeper ablation in follicular lesions, which is not feasible with dermabrasion. Moreover, the treatment of certain areas, such as the upper trunk area or the neck, is limited because of the risk of scar formation.

Recent case reports have advocated the use of carbon dioxide laser vaporization in the treatment of HHD and DD,1517 a procedure that could compensate for some of the disadvantages of dermabrasion. However, carbon dioxide laser vaporization, even in pulsed mode, leaves residual thermal damage, especially with deeper tissue removal, and therefore increases the risk of scar formation and prolonged wound healing. In contrast, erbium:YAG laser ablation, operating at a wavelength of 2.94 µm, combines the most efficacious stepwise etching of the skin surface with the least thermal damage owing to its unique absorption characteristics in tissue water.18,19 This technique should therefore allow the precisely controlled removal of lesions in both HHD and DD and limit the injury in widespread lesions or in those located on areas prone to keloid formation. We decided to treat 4 patients (2 with HHD and 2 with DD) with pulsed 2.94-µm erbium:YAG laser ablation and found this approach to be of special advantage in patients with DD.

REPORT OF CASES

Four patients (2 men and 2 women) with characteristic clinical and histological lesions of chronic recalcitrant DD and HHD were included in our study. The medical history of all 4 patients revealed that they had received topical treatment with corticosteroids and/or antimicrobial agents but that complete remission had not been achieved in any of them.

CASE 1

A 57-year-old woman presented with a 12-year history of recurrent, pruritic, unilateral, zosteriform, erythematous papules in the right axilla, scapular region, and upper arm area. The histological findings in multiple biopsy specimens were consistent with the clinical diagnosis of DD.

CASE 2

A 56-year-old woman presented with multiple hyperkeratotic, brownish red papules that involved the trunk and extremities and coalesced to wartlike plaques on the flexural sites and the neck (Figure 1). She complained of severe pruritus, which had been resistant to topical treatment that was initiated 2 years ago, when the disease had worsened. Histological examination of the lesions confirmed the diagnosis of DD.

Figure 1.
Patient 2 with typical signs of Darier disease. Left, Lower back area. Right, frontal view of neck area.

Patient 2 with typical signs of Darier disease. Left, Lower back area. Right, frontal view of neck area.

CASE 3

A 47-year-old man presented with a 3-year history of HHD involving the groins, the lateral aspect of the scrotum, and both axillae. He was severely distressed by the malodor of the lesions. Skin biopsy specimens showed the characteristic histological features of familial benign chronic pemphigus.

CASE 4

A 42-year-old man presented with a 3-year history of HHD that affected the groins and both axillae. His family had a history of the disease, and the histological findings were consistent with the diagnosis. Pain, pruritus, and exudation of the lesions, as well as their chronicity, led to unemployment and social retirement.

TECHNIQUE

After written consent was obtained, erbium:YAG laser ablation was performed with the patients under local anesthesia. To ensure that the expected improvement was the result of the surgical intervention and not attributable to the spontaneous course of the disease, untreated control lesions were left in all 4 patients before complete ablation was performed. After a minimum follow-up of 8 weeks and a successful treatment outcome, the residual areas were treated in further sessions.

Surgery was performed with an erbium:YAG laser (MCL 29 Dermablate; Aesculap Meditec GmbH, Jena, Germany). Depending on the lesions, we used spot sizes varying from 1.6 mm for small papules of DD to 5.0 mm for confluent plaques of HHD, with repetition rates of 5 to 10 Hz and energies between 300 and 1000 mJ, resulting in fluences of 5 to 8.5 J/cm2 per pulse (Table 1). The pulse width used in all treatment sessions was 350 microseconds.

Erbium:YAG Laser Ablation: Treatment and Results
Erbium:YAG Laser Ablation: Treatment and Results

Large areas were treated with the painting technique, which implies an overlap of approximately 30%. Patients 1 and 2 exhibited numerous punctate lesions, which were treated with a point-by-point technique. According to our previous experiences, and in agreement with the observations of others, we also treated a margin of adjacent uninvolved skin. Up to 7 stacked passes (pulse series) per lesion were performed, and the resulting debris was gently removed with saline-soaked gauze.

The clinical end point of the ablation procedure was determined by the disappearance of the brownish papules of DD and the grayish red lesions of HHD and by the appearance of a white tissue layer exhibiting papillary vessels and pinpoint bleeding after several ablation passes. Ablation of all lesions was performed until the papillary dermis was exposed and a slight punctate bleeding was induced.

Postoperatively, the wounds were covered with a nonadhesive dressing (Cuticerin; Beiersdorf AG, Hamburg, Germany) and sulfadiazine-silver cream. The patients did not receive systemic or topical antibiotics. The dressings were used for approximately 10 to 12 days, depending on the degree of reepithelialization. Dressings were changed every day and cleansed with saline-soaked gauze. In contrast to resurfacing procedures for other indications, corticosteroid formulations were not applied to exclude the possibility that any improvement was due to their anti-inflammatory effects.

RESULTS

Laser test ablations were successful in all patients and showed complete regression within the ablated areas, whereas the untreated sites were still affected. In patients 1, 2, and 3, complementary laser removal of control lesions led to excellent results (Figure 2), and the treated areas showed no recurrence during follow-up (Table 1). No adverse effects (eg, wound infection, hyperpigmentation, or scarring), other than slight hypopigmentation of the cubital fossa and the popliteal cavity in patient 2, and a few atrophic hypopigmented spots after deeper ablation in patient 1, occurred during the period of observation. It is noteworthy that even the plaquelike areas on the ventral aspect of the neck of patient 2 could be cleared completely without any adverse effects even though this region is at high risk for scar formation (Figure 2, right). Both patients with DD also experienced complete relief from itching. It was interesting to observe that ablation of solitary follicular hyperkeratotic papules in the patients with DD resulted in a "wicklike" situs represented by a small prominent keratotic core in the center of the lesion and needed additional focused single pulses for removal. This "wick phenomenon" is likely to be caused by reduced water content (absorbing target) and consequently by less effective ablation within the central hyperkeratotic follicular area.

Figure 2.
Patient 2, 18 months after erbium:YAG laser ablation at 5 J/cm2 with up to 7 stacked passes. Left, Lower back area. Right, Frontal view of neck area.

Patient 2, 18 months after erbium:YAG laser ablation at 5 J/cm2 with up to 7 stacked passes. Left, Lower back area. Right, Frontal view of neck area.

In patient 3, who had HHD, a complete remission of the affected sites was achieved after ablation and no disease activity was detected during more than 1 year of follow-up, whereas in patient 4, some areas recurred at the edges and adjacent to the treated sites, requiring an additional session.

In all 4 patients, the clinical diagnosis was confirmed by histological examination, which revealed the characteristic findings of DD and HHD (Figure 3). Biopsy specimens were obtained from patient 2 immediately after laser ablation and showed the removal of the entire epidermis and stratum papillare, preserving adnexal structures (Figure 4). Only minimal signs of thermal damage were present in the underlying dermis. Eighteen months after the laser procedure, control biopsy specimens were obtained from the treatment site of patient 2. No signs of DD could be detected by histological examination, and the papillary dermis exhibited only a slight increase of fibrotic tissue (Figure 5).

Figure 3.
Dyskeratosis and suprabasal acantholysis in Darier disease (hematoxylin-eosin, original magnification ×200).

Dyskeratosis and suprabasal acantholysis in Darier disease (hematoxylin-eosin, original magnification ×200).

Figure 4.
Patient 2, immediately after laser ablation, with no significant thermal tissue damage (hematoxylin-eosin, original magnification ×200).

Patient 2, immediately after laser ablation, with no significant thermal tissue damage (hematoxylin-eosin, original magnification ×200).

Figure 5.
Patient 2. Biopsy specimen of a treated lesion 18 months after laser ablation. No signs of Darier disease and only slight fibrosis of the upper dermis (hematoxylin-eosin, original magnification ×100).

Patient 2. Biopsy specimen of a treated lesion 18 months after laser ablation. No signs of Darier disease and only slight fibrosis of the upper dermis (hematoxylin-eosin, original magnification ×100).

Eight months after laser ablation, the control biopsy specimens from patient 1 revealed the same results as those from patient 2. Unfortunately, both patients with HHD refused to undergo additional biopsies.

COMMENT

It has been shown by several authors that surgical removal of lesions can achieve successful treatment results in both HHD and DD. Since a complete excision of the involved skin area is not possible in the majority of cases, a variety of shaving and destructive techniques has been introduced, with varying outcome, since each technique has its specific limits, depending on the individual prerequisites of a given lesion. Recent progress in pulsed laser resurfacing procedures has led to the development of more refined techniques that allow highly controlled, selective ablation of the skin, even on critical sites of the body surface where dermabrasion might be impossible or where thermal vaporization could induce unwarranted tissue trauma and interfere with wound healing. In experimental and clinical work, pulsed skin ablation at a laser wavelength of 2.94 µm (absorption peak of tissue water) has been shown to combine a stepwise char-free ablation with the possibility of producing circumscribed deeper crater lesions without cumulative coagulation, even after serial pulses.

Our experience in patients with HHD and DD has confirmed that these advantages are of special value in treating thicker recalcitrant lesions, for which deeper ablation is required, as well as in treating papular lesions located on critical sites. Carbon dioxide laser removal, in contrast, even in pulsed modes, can produce cumulative necrosis after serial pulsing (usually more than 3 passes) owing to tissue desiccation with loss of absorbing water on the irradiated surface.18,19

Therefore, thermal laser vaporization and electrodesiccation are limited in deeper lesions, where a risk of hypertrophic scar or keloid formation has to be considered. We did not observe the development of hypertrophic scars in our patients, which was reported to occur after carbon dioxide laser vaporization in a patient with familial benign chronic pemphigus.17

On the other hand, dermabrasion is unsatisfactory in treating papular lesions and in critical sites, and therefore remains of restricted value in most cases that present with typical distribution patterns of DD. To our knowledge, there have been only 2 reports of patients with DD who were treated with laser surgery.16 In contrast to those 2 cases, we did not administer any concomitant therapy that might influence the spontaneous course of the disease.

Long-term follow-up showed excellent results, with complete remission in 3 patients—2 with DD and 1 with HHD—and partial remission in 1 patient with HHD. The exact mechanism of how the removal of lesional skin contributes to the therapeutic success is as yet unknown. We do not agree with the view of other authors that necrosis and the subsequent fibrosis of the papillary dermis represent a prerequisite for improvement.17

It is more likely that a critical depth of amount of tissue removal is essential and does not necessarily represent tissue necrosis. Our histological findings showed only minimal thermal damage after ablation and slight fibrosis of the papillary dermis after wound healing in ablation craters of DD. Therefore, we were even encouraged to treat the ventral neck area of 1 patient, and complete remission was achieved without any adverse effects (Figure 2, right). The clinical results, as well as the histological findings, confirm that erbium:YAG laser ablation is highly controllable owing to an extremely low ablation threshold, which enables a procedure to be carried out in "micrometer steps." Therefore, the ablation depth corresponds well to the overall amount of tissue destruction, since the relative amount of additional underlying damage is negligible. This result is in contrast to the outcome that is seen with superficial carbon dioxide laser vaporization, where cumulative damage due to tissue heating has to be carefully considered, especially with deeper lesions and additional laser pulses.

In our opinion, erbium:YAG laser ablation represents a very effective and safe therapeutic modality for the treatment of HHD and DD. Fast ablation of large areas, as well as point-by-point removal of keratotic papules and localized deeper ablation, if necessary, is another advantage of the erbium:YAG laser that contributes to the superiority of the method in comparison with abrasive methods or carbon dioxide laser vaporization.

Back to top
Article Information

Accepted for publication December 20, 1998.

Reprints: Roland Kaufmann, MD, Department of Dermatology, J. W. Goethe University, Theodor-Stern-Kai 7, D-60590 Frankfurt/M, Germany.

References
1.
Phillips  SBBaden  HP Darier-White disease (keratosis follicularis) and miscellaneous hyperkeratotic disorders. Fitzpatrick  TBEisen  AZWolff  KFreedberg  IMAusten  KFeds.Dermatology in General Medicine. 4th ed. New York, NY McGraw-Hill International Book Co1993;537- 541
2.
Burge  SMWilkinson  JD Darier-White disease: a review of the clinical features in 163 patients. J Am Acad Dermatol. 1992;2740- 50Article
3.
Burge  SM Hailey-Hailey disease: the clinical features, response to treatment and prognosis. Br J Dermatol. 1992;126275- 282Article
4.
Johnson  B  JrHonig  P Congenital diseases (genodermatoses). Elder  DElenitsas  RJaworsky  CJohnson  B  Jreds.Lever's Histopathology of the Skin. 8th ed. Philadelphia, Pa Lippincott-Raven Publishers1997;131- 134
5.
Welsh  EAIkeda  SPeluso  AM  et al.  Hailey-Hailey disease is not allelic to Darier's disease. J Invest Dermatol. 1994;102992- 993Article
6.
Biro  FAMaday  P Familial chronic pemphigus. Arch Dermatol. 1969;100385Article
7.
Crotty  CPScheen  SRMasson  JKWinkelmann  RK Surgical treatment of familial benign chronic pemphigus. Arch Dermatol. 1981;117540- 542Article
8.
Cohen  KIKraemer  KHPeck  GL Cornifying Darier disease: a unique variant. Arch Dermatol. 1976;112504- 506Article
9.
Quitadamo  MJSpencer  SK Surgical management of Hailey-Hailey disease. J Am Acad Dermatol. 1991;25342- 343Article
10.
Zachariae  H Dermabrasion in Darier's disease. Acta Derm Venereol (Stockh). 1979;59184- 186
11.
Larnder  DA Darier's disease treated by dermabrasion [abstract]. Br J Dermatol. 1959;7173- 74
12.
Zachariae  H Dermabrasion of Hailey-Hailey disease and Darier's disease. J Am Acad Dermatol. 1992;27136Article
13.
Hamm  HMetze  DBröcker  EB Hailey-Hailey disease eradication by dermabrasion. Arch Dermatol. 1994;1301143- 1149Article
14.
Kirtschig  GGieler  UHapple  R Treatment of Hailey-Hailey disease by dermabrasion. J Am Acad Dermatol. 1993;28784- 786Article
15.
Don  PCCarney  PSLynch  WSZaim  MTHassan  MO Carbon dioxide laser abrasion: a new approach to management of familial benign chronic pemphigus (Hailey-Hailey disease). J Dermatol Surg Oncol. 1987;131187- 1194Article
16.
McElroy  JAMehregan  DARoenigk  RK Carbon dioxide laser vaporization of recalcitrant symptomatic plaques of Hailey-Hailey disease and Darier's disease. J Am Acad Dermatol. 1990;23893- 897Article
17.
Kartamaa  MReitamo  S Familial benign chronic pemphigus (Hailey-Hailey disease): treatment with carbon dioxide laser vaporization. Arch Dermatol. 1992;128646- 648Article
18.
Kaufmann  RHartmann  AHibst  R Cutting and skin-ablative properties of pulsed mid-infrared laser surgery. J Dermatol Surg Oncol. 1994;20112- 118Article
19.
Kaufmann  RHibst  R Pulsed erbium:YAG laser ablation in cutaneous surgery. Laser Surg Med. 1996;19324- 330Article
×